TABLE 2.
Patient | Age | Gender | Eye | Diagnosis | Follow-up (months) |
Number of Injections |
Phakic Statusa | Prior Injectionsa,b |
Active Uveitisa |
Diabetica,c | Concurrent Topical Treatmenta,b |
Concurrent Systemic Treatmenta,b |
Prior Vitrectomya |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
20 | 17 | F | OS | Pars planitis | 13 | 4 | Phakic | None | Yes | No | Prednisolone | CSA, MTX | No |
21 | 58 | F | OS | Idiopathic panuveitis | 1 | 1 | Pseudophakic | None | Yes | No | Prednisolone | Prednisone, MTX | No |
22 | 81 | F | OD | Toxoplasmosis | 3 | 1 | Aphakic | None | No | No | None | None | No |
23 | 57 | F | OD | Fuchs uveitis syndrome | 1 | 1 | Pseudophakic | IVTA ×3 | Yes | No | MP, ketorolac | None | No |
24 | 68 | F | OS | Idiopathic chronic iridocyclitis/vitreitis |
8 | 2 | Pseudophakic | None | Yes | No | Prednisolone, nepafenac |
None | No |
25 | 72 | M | OS | Idiopathic retinal vasculitis |
13 | 1 | Pseudophakic | None | Yes | Yes | Loteprednol, diclofenac |
None | Yes |
26 | 44 | M | OD | CMVR/immune-recovery uveitis |
10 | 2 | Phakic | STTA ×3 | Yes | No | None | None | No |
27a | 33 | M | OD | Pars planitis | 16 | 2 | Pseudophakic | None | No | No | Prednisolone, nepafenac |
Mycophenolate | Yes |
27b | 33 | M | OS | Pars planitis | 14 | 2 | Pseudophakic | None | Yes | No | Prednisolone, nepafenac |
Mycophenolate | No |
28 | 67 | M | OS | Sarcoid panuveitis | 9 | 2 | Pseudophakic | STTA ×1 | Yes | No | None | None | Yes |
29 | 79 | F | OS | Chronic idiopathic anterior/intermediate uveitis |
13 | 2 | Pseudophakic | None | Yes | No | Nepafenac | MTX | No |
30a | 83 | F | OD | Idiopathic occlusive vasculitis |
20 | 4 | Pseudophakic | None | Yes | No | None | Prednisone | No |
30b | 83 | F | OS | Idiopathic occlusive vasculitis |
20 | 1 | Pseudophakic | None | Yes | No | None | Prednisone | No |
CMVR = cytomegalovirus retinitis; CSA = cyclosporine A; IVTA = intravitreal triamcinolone; MP = methylprednisolone; MTX = methotrexate; OD = right eye; OS = left eye; STTA = sub-Tenon triamcinolone.
None of these variables statistically influenced outcomes with respect to visual acuity or macular thickness.
Limited to anti-inflammatory therapies.
Refers to the presence or absence of diabetes mellitus; no patients had diabetic retinopathy.